Hyderabad, India (Press Release) – NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce that it has reached a Settlement Agreement with Onyx Thera­peutics, Inc. on patent lit­i­ga­tion related to generic versions of 10mg, 30mg and 60mg of Kyprolis®. NATCO has partnered with Breckenridge Pharma­ceu­tical, Inc., who will mar­ket the prod­uct in the United States.

The parties have reached a Settlement Agreement and the District Court case has been dismissed. By virtue of the settlement, NATCO and Breckenridge have been granted a license permitting the launch of their generic car­filz­o­mib prod­uct on a date that is held as con­fi­den­tial in 2027 or sooner depending on cer­tain occurrences. The parties cannot make further comment as to the terms of the Settlement Agreement.

NATCO believes that its 10mg ANDA is sole first to file and could be eli­gible for 180-days mar­ket­ing exclusivity for the 10mg strength under cer­tain cir­cum­stances.

Kyprolis® reportedly had sales of USD 586 million for the year ending De­cem­ber 2018 in the United States.

Kyprolis® is a registered trademark of Onyx Thera­peutics, Inc.

Source: NATCO.